About Piribo.
Piribo is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 6,000 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.
Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report which finds that combination pharmaceutical products, or fixed-dose combinations (FDCs), are highly beneficial and have gained acceptance as well.
Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report which finds that the global insulin market is expected to witness double-digit growth during 2007-2012.
Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report which anticipates that there will be a boom between 2010 and 2015 in the nanobiotechnology market.
Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report which contains over 400 links to online copies of actual merger and acquisition contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.
Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report on the latest forecasts in the world pharmaceutical packaging industry.
Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report on the cancer therapeutics market. “Cancer Therapeutics: The Worldwide Market” forecasts that the cancer therapeutics market will grow from around $46 billion in 2006 to more than $89 billion by 2011.
Over $100 billion in revenue of major branded drugs is under threat from new generic products as patents expire over the next five years, says a new report available from Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry,
Satisfied Users & 
Approved Press Releases
